November 25, 2013

Sanofi and Regeneron’s Dupilumab Named “Clinical Advance of the Year” by Scrip Intelligence

 

Sanofi and Regeneron’s Dupilumab Named “Clinical Advance of the Year” by Scrip Intelligence

Paris, France and Tarrytown, NY – November 25, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named “Clinical Advance of the Year” by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical industry publication.